Category Archives: Other

Policy Analysis and Guidance: Yunnan Province’s Revised Technical Guidelines for Chinese Herbal Medicine Quality Standards

Yunnan Province’s Drug Administration has released a revised version of the “Technical Guidelines for the Quality Standards Research of Chinese Herbal Medicines,” aiming to enhance the quality and safety of traditional herbs, promote innovation, and align with national regulatory standards. This revision reflects Yunnan’s strategic focus on leveraging its unique herbal resources and ethnic medical practices to drive industry modernization and internationalization.

Key Policy Revisions

  1. Emphasis on Unique and Ethnic Characteristics
    • Objective: Protect Yunnan’s distinctive herbal advantages and enrich the knowledge base of ethnic medicinal practices.
    • Implementation: The revised guidelines provide comprehensive solutions for organizing and summarizing historical and regional medication habits, linking clinical positioning with safety information through real-world data.
  2. Enhanced Operability
    • Details: Specific requirements for research objectives, methods, and standards have been added, including detailed guidance on historical literature collection, clinical data collection, and toxicity trial requirements.
    • Impact: Facilitates consensus between researchers and regulators, streamlining the standard-setting and revision processes.
  3. Innovation and Technological Integration
    • Encouragement: Reduced barriers for researchers and increased emphasis on leveraging new technologies for accurate identification and component analysis.
    • Outcome: Aims to establish new local standards or elevate existing ones, supporting the modernization and global reach of Yunnan’s herbal industry.
  4. Environmental and Sustainable Development Focus
    • Measures: Emphasizes compliance in sample collection and encourages research samples from cultivation bases to protect ecological resources.

Policy Orientation and Industry Implications
The revised guidelines position Yunnan as a leader in traditional Chinese medicine (TCM) standardization by:

  • Quality Enhancement: Strengthening safety and efficacy through rigorous research protocols.
  • Industry Support: Providing clear pathways for standard development and international market access.
  • Eco-Friendly Practices: Promoting sustainable resource management to ensure long-term supply stability.

Conclusion
Yunnan’s updated framework for herbal medicine standards not only solidifies the province’s role in preserving traditional knowledge but also paves the way for scientific innovation and global competitiveness. Stakeholders in the TCM sector should align with these guidelines to capitalize on Yunnan’s unique ecological and cultural advantages while meeting evolving regulatory expectations.-China Health Reform Pulse

Policy Source: https://mpa.yn.gov.cn/newsite/ZwgkNewsView.aspx?ID=2c531135-46bf-4ad1-b65e-a85c4eea9e64

Policy Analysis and Guidance: Guangdong Province’s Ninth Batch of National Centralized Drug Procurement Renewal

Guangdong Province’s Drug Exchange Center has issued a notice regarding the renewal of the ninth batch of national centralized drug procurement for the second procurement year, effective from March 30, 2025, to March 29, 2026. This policy aims to ensure the continuity of drug supply, maintain quality standards, and streamline procurement processes across healthcare institutions.

Key Policy Measures

  1. Viewing Contracted Procurement Volumes
    • Process: Medical institutions and selected enterprises can use CA certificates to log into Guangdong’s tender and procurement subsystem to view contracted procurement volumes. This transparency helps in planning and managing drug distribution efficiently.
  2. Tripartite Contract Signing
    • Procedure: Medical institutions must initiate tripartite contracts through the subsystem, with detailed operational guidance available on the official website. Timely contract completion by all parties is crucial to ensure smooth implementation.
  3. Quality and Supply Assurance
    • Responsibility: Drug manufacturers are held accountable for the quality and timely supply of medications. They must ensure coverage across all participating healthcare institutions in the province, emphasizing reliability in the supply chain.

Policy Orientation and Industry Implications
The renewal initiative underscores Guangdong’s commitment to:

  • Supply Stability: Ensuring uninterrupted drug supply to healthcare facilities.
  • Quality Control: Maintaining high standards for drug quality through clear accountability.
  • Efficiency: Streamlining procurement processes to enhance operational effectiveness.

Conclusion
Guangdong’s approach to centralized drug procurement renewal sets a precedent for regional pharmaceutical management, emphasizing reliability, quality, and efficiency. Stakeholders should adhere to these guidelines to optimize compliance and ensure patient access to essential medications.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1905839740230307840

Policy Analysis and Guidance: Jiangsu Province’s Medical Device Quality and Safety Assessment Measures

Jiangsu Provincial Drug Administration has issued new measures for assessing the quality and safety responsibilities of medical device manufacturers. The “Jiangsu Province Medical Device Production Enterprises Quality and Safety Main Responsibility Assessment Measures” aim to strengthen enterprises’ responsibility for quality and safety, enhance regulatory precision, and promote the high-quality development of the medical device industry.

Key Policy Measures

  1. Annual Assessment System
    • Frequency: Enterprises are assessed annually based on their performance in fulfilling quality and safety responsibilities.
    • Scope: The assessment covers the period from January 1 to December 31 of the previous year. New enterprises and those that have been out of production for over a year are excluded.
  2. Three-Tier Grading System
    • Grades: Enterprises are classified into three levels: A (excellent), B (good), and C (average).
    • Criteria:
      – A Grade: Score of 90 or above.
      – B Grade: Score between 75 and 89.
      – C Grade: Score below 75.
  3. Immediate Downgrade Mechanism
    • Circumstances: Enterprises found with serious violations, product quality issues leading to severe incidents, or failure to recall defective products will be immediately downgraded to C.
  4. Self-Assessment and Reporting
    • Process: Enterprises must complete self-assessment by March 31 each year and submit reports to the provincial drug administration’s regulatory platform.
  5. Regulatory Review and On-Site Inspection
    • Procedure: Local market supervision bureaus and inspection branches will review self-assessment reports and conduct on-site inspections on no less than 3% of enterprises by May 31.
  6. Incentive and Constraint Mechanisms
    • Measures: Enterprises of different grades will face corresponding incentives or constraints to encourage continuous improvement in quality and safety management.

Policy Orientation and Industry Implications
The new assessment measures highlight Jiangsu’s strategic focus on:

  • Quality and Safety: Prioritizing product reliability and consumer protection.
  • Regulatory Precision: Enhancing the scientific and precise nature of industry oversight.
  • Industry Upgrading: Driving the medical device sector toward higher quality and innovation.-China Health Reform Pulse

Policy Source: http://da.jiangsu.gov.cn/art/2025/3/28/art_84620_11527826.html